Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints

16 Nov 2022

Abstract excerpt

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) induce cytotoxic effects as single agents in tumors characterized by defective repair of DNA double-strand breaks deriving from BRCA1/2 mutations or other abnormalities in genes associated with homologous recombination. Preclinical studies have shown that PARPi-induced DNA damage may affect the tumor immune microenvironment and immune-mediated anti-tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36428727
DOI: 10.3390/cancers14225633

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune CheckpointsPMID 36428727Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical ImplicationsSemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid TumorsSemantic proximity Read ↗

Development of PARP and Immune-Checkpoint Inhibitor CombinationsSemantic proximity Read ↗

Recent advancements in PARP inhibitors-based targeted cancer therapySemantic proximity Read ↗

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.Semantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

Update on Combination Strategies of PARP InhibitorsSemantic proximity Read ↗

PARP inhibition and immunotherapy: a promising duo in fighting cancerSemantic proximity Read ↗

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical ApplicationsSemantic proximity Read ↗

PARP inhibitors for anticancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.